The 'copper uglies' from GHK-Cu peptides, fact-checked

What did @angiee.calderonx actually say?

She's been sitting on a vial of GHK-Cu (copper peptide, likely KLOW) for two weeks out of fear. The fear is specific: she's heard about something called the "copper uglies," a term circulating in peptide communities to describe a purported breakout or skin worsening phase when starting copper peptide therapy. She also mentions she's been off spironolactone for about six weeks and doesn't want to trigger her skin. At the end, she notes the product stings on injection or application. That's the whole claim, really: copper peptides might make skin worse before it gets better, and she's hoping it doesn't happen to her.

To her credit, she's not making a bold therapeutic promise. She's expressing anxiety about a side effect she's heard about secondhand. That's a more honest framing than most peptide content on TikTok, which tends to skip straight to miracle claims.

Does the science back this up?

The "copper uglies" concept is real-ish, but the evidence behind it is thin and mostly anecdotal. Here's what we actually know from research.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is one of the more studied cosmetic peptides. It has demonstrated wound-healing, anti-inflammatory, and collagen-stimulating activity in cell and animal studies. A 2018 review by Pickart and Margolina in Biomolecules summarized decades of GHK-Cu research, showing it upregulates collagen, laminin, and fibronectin production while also promoting skin remodeling. That remodeling part is key.

Skin remodeling can involve a temporary increase in matrix metalloproteinases (MMPs), enzymes that break down old collagen before new collagen is laid down. In theory, this could cause a temporary worsening in skin texture or tone. Some dermatologists have pointed to this mechanism as a plausible explanation for the "uglies" phase. But here's the catch: no controlled clinical trial has specifically documented a "copper uglies" period as a defined phenomenon with measurable onset, duration, or severity. What exists is mechanistic plausibility plus a lot of forum posts.

What did they get wrong (or right)?

She got the anxiety right. A purge-like response from GHK-Cu is biologically plausible, and being cautious after stopping spironolactone is genuinely sensible. Spironolactone suppresses androgen-driven sebum production, so coming off it does carry a real risk of hormonal skin changes over the following weeks to months. A 2021 study by Burns et al. in the Journal of the American Academy of Dermatology confirmed that acne often rebounds after spironolactone discontinuation, sometimes worse than baseline.

Where the content gets shaky is the implicit framework that any worsening is a necessary or predictable phase of copper peptide use. That framing, common in peptide communities, can lead people to push through side effects that might actually warrant stopping. If your skin worsens significantly after starting any topical or injectable peptide, that's a signal worth investigating, not automatically tolerating.

Also: the stinging she mentions. GHK-Cu solutions, particularly injectable formulations, can cause injection-site discomfort. That's normal for many peptide injections. It does not confirm efficacy.

What should you actually know?

A few things worth understanding before you start any copper peptide regimen, especially injectable formulations like what she appears to be using.

• GHK-Cu has a reasonable evidence base for wound healing and collagen support, mostly from in vitro and animal studies. Human clinical data is more limited.
• The "copper uglies" is a community term, not a clinical diagnosis. There is no peer-reviewed literature documenting it as a predictable phase of treatment.
• If you're transitioning off a hormonal medication like spironolactone, your skin is already in flux. Adding a new active agent during that window makes it harder to isolate what's causing any changes.
• Injectable peptides sourced outside of a licensed telehealth or clinical setting carry compounding quality and sterility risks that topical formulations do not.
• Stinging at the injection site can be normal, but stinging does not mean the product is working.

If you're considering GHK-Cu for skin or wound-related goals, talk to a licensed provider who can evaluate your full picture, including what you've recently stopped taking.